Vertex Pharmaceuticals Incorporated (LON: 0QZU)

London flag London · Delayed Price · Currency is GBP · Price in USD
397.00
+6.17 (1.58%)
Dec 23, 2024, 7:15 AM BST
-1.56%
Market Cap 81.38B
Revenue (ttm) 7.93B
Net Income (ttm) -357.98M
Shares Out n/a
EPS (ttm) -1.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 68
Open 404.42
Previous Close 390.83
Day's Range 397.00 - 404.42
52-Week Range 290.87 - 446.29
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 6, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underl... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1989
Employees 5,400
Stock Exchange London Stock Exchange
Ticker Symbol 0QZU
Full Company Profile

Financial Performance

In 2023, Vertex Pharmaceuticals's revenue was $9.87 billion, an increase of 10.51% compared to the previous year's $8.93 billion. Earnings were $3.62 billion, an increase of 8.96%.

Financial numbers in USD Financial Statements

News

Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio? Novo Nordisk A/S (NYSE: NVO) shares dipped 20.52% after the company released headline results fro...

23 hours ago - Benzinga

Vertex wins approval of new cystic fibrosis therapy Alyftrek

Vertex Pharmaceuticals' Alyftrek has been approved as a new cystic fibrosis treatment taken once daily. Read more here.

2 days ago - Seeking Alpha

Vertex Pharmaceuticals (VRTX) Gains FDA Approval for ALYFTREK™

Vertex Pharmaceuticals (VRTX) Gains FDA Approval for ALYFTREK™

2 days ago - GuruFocus

Vertex Pharmaceuticals Inc (VRTX) Announces FDA Approval of ALYFTREK for Cystic Fibrosis Treatment

Vertex Pharmaceuticals Inc (VRTX) Announces FDA Approval of ALYFTREK for Cystic Fibrosis Treatment

2 days ago - GuruFocus

US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in ...

2 days ago - Reuters

Vertex Pharmaceuticals Inc (VRTX) Expands TRIKAFTA® Approval for Cystic Fibrosis Treatment

Vertex Pharmaceuticals Inc (VRTX) Expands TRIKAFTA® Approval for Cystic Fibrosis Treatment

2 days ago - GuruFocus

Vertex Pharmaceuticals (VRTX) Stock Surges Amid Mixed Analyst Ratings

Vertex Pharmaceuticals (VRTX) Stock Surges Amid Mixed Analyst Ratings

2 days ago - GuruFocus

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor...

2 days ago - Business Wire

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaft...

2 days ago - Business Wire

Shareholders that lost money on Vertex Pharmaceuticals Incorporated (VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTX

NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRT...

2 days ago - Accesswire

Vertex Pharmaceuticals Incorporated Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VRTX

NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRT...

2 days ago - Accesswire

Cramer's Mad Dash: Vertex Pharmaceuticals

CNBC's Jim Cramer delivers his daily Mad Dash.

2 days ago - CNBC Television

Cramers Mad Dash: Vertex Pharmaceuticals

CNBCs Jim Cramer delivers his daily Mad Dash.

2 days ago - CNBC

Vertex Pharmaceuticals Inc. (VRTX) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

BOSTON, MA / ACCESSWIRE / December 20, 2024 / Block & Leviton is investigating Vertex Pharmaceuticals Inc. (Nasdaq:VRTX) for potential securities law violations. Investors who have lost money in their...

3 days ago - Accesswire

Oppenheimer Downgrades Vertex Pharmaceuticals (VRTX) After Study Results

Oppenheimer Downgrades Vertex Pharmaceuticals (VRTX) After Study Results

3 days ago - GuruFocus

Vertex downgraded to perform by Oppenheimer

Financial writer downgrades Vertex (VRTX) based on Phase 2 data for suzetrigrine, citing uncertain benefit/risk profile in LSR treatment.

3 days ago - Seeking Alpha

Stocks on the Move: Vertex Pharma, Shake Shack, Zoom, Lennar and Home Depot

The CNBC 'Halftime Report' Investment Committee weighs in on 'Stocks on the Move' and their picks.

3 days ago - CNBC Television

Stocks on the Move: Vertex Pharma, Shake Shack, Zoom, Lennar and Home Depot

The CNBC 'Halftime Report' Investment Committee weighs in on 'Stocks on the Move' and their picks.

3 days ago - CNBC

Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?

On Thursday, Vertex Pharmaceuticals Incorporated  VRTX announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower bac...

3 days ago - Benzinga

Vertex Pharmaceuticals Faces Legal Scrutiny Over Clinical Trial Results

Vertex Pharmaceuticals Faces Legal Scrutiny Over Clinical Trial Results

3 days ago - GuruFocus

Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

Block & Leviton is investigating Vertex Pharmaceuticals (Nasdaq: VRTX) for potential securities fraud. Investors who lost money should contact the firm.

3 days ago - GlobeNewsWire

Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.

3 days ago - Investopedia

Cramer's Stop Trading: Vertex Pharmaceuticals

CNBC's Jim Cramer explains why he is keeping an eye on shares of Vertex Pharmaceuticals.

3 days ago - CNBC Television

Cramers Stop Trading: Vertex Pharmaceuticals

CNBCs Jim Cramer explains why he is keeping an eye on shares of Vertex Pharmaceuticals.

3 days ago - CNBC